 | Vol. 10.21 – 31 May, 2022 |
| |
|
|
| Researchers reported a cancer vaccine that induced a coordinated attack by diverse T cell and NK cell populations. The vaccine targets the MICA and MICB stress proteins expressed by many human cancers as a result of DNA damage. [Nature] |
|
|
|
 | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators systematically identified more than 340,000 protein families as potentially bioactive with respect to gut inflammation during inflammatory bowel disease, about half of which have not to their knowledge been functionally characterized previously on the basis of homology or experiment. [Nature] |
|
|
|
| Scientists mapped genetic effects on gene expression using single-cell transcriptomics. They profiled 655,349 CD4+ T cells, capturing transcriptional states of unstimulated cells and three time points of cell activation in 119 healthy individuals. [Nature Genetics] |
|
|
|
| Although clear cell renal cell carcinoma (RCC) was infiltrated by exhaustion-phenotype CD8+ T cells that negatively correlated with patient prognosis, chromophobe RCC had abundant infiltration of granzyme A-expressing intraepithelial type 1 innate lymphoid cells that positively associated with patient survival. [Nature Immunology] |
|
|
|
| Researchers identified NLRP11 as an essential component of the NLRP3 inflammasome in human macrophages. [Nature Immunology] |
|
|
|
| The authors demonstrated that a diverse intestinal microbiome early after allogeneic hematopoietic cell transplantation (HCT) was associated with an increased number of innate-like mucosal-associated invariant T (MAIT) cells, which were in turn associated with improved overall survival. [Science Translational Medicine] |
|
|
|
| Scientists investigated whether in human head and neck squamous cell carcinoma, high levels of expression of stress keratin 17 were associated with poor survival and resistance to immunotherapy. [Clinical Cancer Research] |
|
|
|
| Researchers showed that T follicular helper cells expressed hematopoietic prostaglandin D2 synthase in a pSTAT1/pSTAT3-dependent manner. [Cancer Immunology Research] |
|
|
|
| Higher CD73 expression in non-small cell lung cancer cancer cells and patient-derived organoids with EGFR mutation, KRAS mutation or ALK-rearrangement. [European Journal of Cancer] |
|
|
|
| The authors indirectly compared the effects of immune checkpoint inhibitors alone (ICI) and ICI-combined chemotherapy in patients with non-small cell lung cancer (NSCLC) who had high programmed death-ligand 1 (PD-L1) expression through network meta-analyses. [British Journal of Cancer] |
|
|
|
| Researchers showed that while NK cells were largely resistant to the upregulation of CD73, CD73 expression was inducible on NK cells in response to CD73 on cancer cells, and these cells were associated with distinct functional signatures. [Cancer Immunology Immunotherapy] |
|
|
|
| Investigators suggested that the exclusion of CD226-expressing cells during regulatory T cell (Treg) sorting yielded a population with increased purity, lineage stability, and suppressive capabilities, which may have benefited Treg adoptive cell therapy for the treatment of autoimmune diseases. [Frontiers in Immunology] |
|
|
|
|
| The authors discuss the molecular mechanisms whereby cancer cells shape a myeloid cell-mediated immunosuppressive tumor microenvironment and, reciprocally, how such myeloid cells affect tumor progression and immunotherapy efficiency in glioblastoma. [Trends in Cancer] |
|
|
|
|
| Umoja Biopharma, Inc. and Lupagen, Inc. announced they have entered into a collaboration to evaluate extracorporeal in vivo delivery as a potential additional route of administration for Umoja’s VivoVec particles using Lupagen’s Side CAR-T™ technology. [Umoja Biopharma, Inc.] |
|
|
|
| Quoin Pharmaceuticals, Ltd. announced it has signed a second exclusive research agreement with the Queensland University of Technology, Australia. [Quoin Pharmaceuticals, Ltd.] |
|
|
|
| DxTerity Diagnostics announced the opening of enrollment in Empower Lupus Erythematous Patients Via Allowing RemoTe Evaluation (ELEVATE), a new observational clinical study for patients with systemic lupus erythematosus. [DxTerity Diagnostics (Cision US, Inc.)] |
|
|
|
|
| June 26 – 28, 2022 Basel, Switzerland |
|
|
|
|
|
| Human Technopole – Milan, Italy |
|
|
|
| Van Andel Institute – Grand Rapids, Michigan, United States |
|
|
|
| Albert Einstein College of Medicine – New York, New York, United States |
|
|
|
| The Ohio State University – Columbus, Ohio, United States |
|
|
|
| National Institute of Allergy and Infectious Diseases – Bethesda, Maryland, United States |
|
|
|
|